Thomas Krarup

NICE already recommended Genedrive as the point-of-care test of choice in its draft guidance before clopidogrel administration in the management of Ischemic Stroke (IS) and Transient Ischaemic Attack (TIA) patients. Really great achievement outperforming the laboratory test with respect to accuracy! #diagnostics #pharmacogenetics #PGx #pointofcare #POCT #stroke #nhs

6

1 Kommentar

please find information about the merger of palleos healthcare and OCT Clinical also on youtube. For translation into english please drop me a message. #clinicalresearch #merger #octclinical #palleoshealthcare #croeurope #croservices #oncology

8

2 Kommentarer

Tomorrow (7/17) between 8.30 am - 10:00 am PDT, Clear Labs' Chief Scientific Officer/Chief Operating Officer Ramin Khaksar and Aviagen's Laboratory Director Lola Crespo will be co-presenting at #IAFP2024 Symposia S50 about how proactive #SalmonellaSerotyping using the #ClearSafety solution can enhance consumer protection with data-enriched insights and support unified efforts in policy, industry, and biotech in Room 104AB. See you there! International Association for Food Protection #Salmonella #Serotyping #Listeria #Surveillance #NextGenerationSequencing #NGS #tNGS #LiberateGenomics #FoodSafety #Automation

26

Using 'representation vectors' instead of prompt engineering to modulate #LLM responses enables tuneable behavior: https://lnkd.in/eUwSUvtg

10

1 Kommentar

Unlocking the Future of Cell and Gene Therapy with #CDMOPartnerships! In an engaging interview, Andy Lewin, Chief Commercial Officer of Pluri #CDMO, dives deep into the perpetual challenges of cell and gene therapy development. Andy emphasizes the critical role of CDMO partnerships in tackling cost, quality, and time concerns. He highlights the importance of fostering true collaboration, where CDMOs become integral to the client’s team, contributing to the long-term success of advanced therapy products. 👉 Discover insights into: - Key manufacturing challenges in cell and gene therapy - The importance of early CDMO partnerships - Strategies for planning success in therapy development - Navigating the evolving regulatory landscape 💬 Don't miss out on this valuable discussion! https://lnkd.in/dNdC6Qmh #CellAndGeneTherapy #PharmaceuticalDevelopment #Biotechnology #HealthcareInnovation

5

🔔 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗟𝗮𝘂𝗻𝗰𝗵!   BIOSHARE SOLUTIONS is delighted to launch Internationally ID SOLUTIONS new assay: 𝗜𝗗𝗘𝗦𝗥𝟭, 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗮𝘀𝘀𝗮𝘆 𝗼𝗻 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗼𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗮 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝘀𝗲𝗰𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁 𝗿𝗲𝗽𝗼𝗿𝘁.   ID SOLUTIONS, the expert in liquid biopsy downstream molecular analysis in oncology, offers innovative and targeted solutions for patients with cancer.   IDESR1 is a digital PCR assay, detecting activating ESR1 mutations targeting the hotspot found in exon 8 and the E380Q mutation in plasma samples.   COMING NEXT: IDESR1(+): Will detect the same mutations as IDESR1 𝗮𝗻𝗱 “𝗿𝗮𝗿𝗲 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀”: 𝗦𝟰𝟲𝟯𝗣, 𝗩𝟰𝟮𝟮𝗱𝗲𝗹 𝗮𝗻𝗱 𝗞𝟯𝟬𝟯𝗥.   ✅ 𝗘𝗮𝘀𝘆-𝘁𝗼-𝘂𝘀𝗲 ✅ 𝗛𝗶𝗴𝗵𝗹𝘆 𝘀𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗲 ✅ 𝗢𝗻𝗲 𝘄𝗲𝗹𝗹 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻  ✅ 𝗣𝗮𝘁𝗲𝗻𝘁𝗲𝗱 “𝗜𝗖𝗘” 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹   𝘍𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺. Not for use in diagnostic procedures.   Find out more: https://lnkd.in/dWEg2Wg2   Do not hesitate to contact us: https://lnkd.in/dEWpjvp6   #biosharesolutions #idsolutions #idsolutionsoncology #esr1 #oncology #breastcancer #dpcr #multiplex #montpellier #marseille #distribution #personalisedmedicine #cancer

34

Happy to see that Gencovery is today identified in the growing market of #realwordevidence solutions. Regarding #health, I personally attach a great importance in the making real-world evidences and related #data more accessible for the end benefit of patients ❤️! The purpose of Gencovery's digital platform Constellab is to revolutionize digital life science industries (#agronomy, #nutrition, #environment, #health) by providing a universal access to any data, in particular real-world data to unlock the full potential of #AI and #insilico models. 👉 SAVE THE DATA 🗓 : We organize at #LifeHubLyon on 9 - 10 sept the 3rd edition of #ConstellabConnect with a focus on real-world evidences data. Catherine Sirven Simon Maechling Philippe Méresse

31

1 Kommentar

Exciting Collaboration Update! 🚀 Bayer and Evotec are taking their partnership to the next level by focusing on Precision Cardiology. They’re leveraging cutting-edge #iPSC disease modelling to identify new targets for innovative cardiovascular treatments. This strategic move aims to transform patient care in #cardiology with novel, effective therapies. Stay tuned for more breakthroughs from our companies, #together! #PrecisionCardiology #Innovation #HealthcareCollaboration #TogetherForMedicinesThatMatter

239

2 Kommentarer

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/YHVxZ0 showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/bVp892 🤝

25

Read of Day: Gut microbiome and Cancer Immunotherapy. The impact of #Faecalibacterium #prausnitzii on the efficacy of immune checkpoint inhibitors. #gutmicrobiome #ici #cancer #immunotherapy

4

Global Regenerative Medicine (RM) Industry Database - Featuring 1,550+ Companies [Updated for June 2024] - https://lnkd.in/eYxEsiw The regenerative medicine industry has experienced remarkable growth propelled by advancements in cell therapies, gene therapies, stem cell research, tissue engineering, exosome therapeutics, 3D printing, cultured meat production, and beyond. This burgeoning field offers promising solutions for treating a myriad of diseases and injuries by harnessing the body's natural ability to heal and regenerate. This growth is both revolutionizing healthcare by offering new treatment modalities and addressing unmet medical needs on a global scale. The number of RM market competitors keeps growing every month. If you work in this market area, it can be hard to keep up. Thankfully, you can now access the world’s only searchable, sortable database of regenerative medicine companies that is publicly available. This week only, it is available for 50% off.

4

I look forward to learning from industry-leading scientists in the UK, Netherlands, Switzerland, and Germany on antibody discovery, AI, new technologies, and small molecule analysis at the symposia next week and hearing about the latest breakthroughs in #drugdiscovery #drugdevelopment #biotechnology #labelfree

17

SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies - https://lnkd.in/g8RhX7Xc SCG Cell Therapy (SCG) and the A*STAR - Agency for Science, Technology and Research announced the launch joint laboratories for cellular immunotherapies. This collaboration, at a combined funding of close to S$30 million supported under Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE2025), aims to advance the development of induced pluripotent stem cell (iPSC) technology to produce novel cell therapies that meet Good Manufacturing Practice (GMP) standards. The collaboration will also establish a talent development programme to train the next generation of experts in this field, in accordance with current GMP and regulatory requirements. “Cellular immunotherapies herald a new era of regenerative medicine, offering hope for patients with cancers and other serious illnesses. As a key player in T cell receptor (TCR) T cell therapeutics, SCG has developed in-house cGMP manufacturing capabilities to supply high-quality cell therapy products to patients. Through this first-of-its-kind joint collaboration with A*STAR, we bring together A*STAR’s advanced iPSC technology and bioprocessing capabilities with our expertise in GMP cell therapy manufacturing and clinical development, furthering our mission to provide affordable off-the-shelf cell therapy treatment options to patients”, said Christy Ma, Chief Strategy Officer of SCG Cell Therapy. “The discovery of iPSCs has revolutionised regenerative medicine, offering the potential for standardised, off-the-shelf cell therapies. Through this collaboration with SCG Cell Therapy, we aim to accelerate the translation of iPSC research into clinically viable therapies and strengthen Singapore’s position as a global leader in cell therapy innovation. By leveraging our complementary expertise and resources, the joint labs will not only advance iPSC technology for scalable, GMP-compliant cell therapy production but also serve as a platform for nurturing the next generation of talent in this transformative field,” said Prof Boon Tong Koh, Executive Director, A*STAR’s BTI. Read more at: https://lnkd.in/g8RhX7Xc #ipsc #celltherapy #stemcell

8

1 Kommentar

We, the team at CellCentric, are pioneering a new approach to treat multiple myeloma, with an oral p300/CBP inhibitor drug, inobrodib. Huge progress has been made in treating the disease, particularly with recent antibody-based therapies (BCMA targeting agents, TCEs). But 75% of people diagnosed still die of the condition. Beyond and alongside existing approaches, there is a need for oral agents with novel modes of action. Community based delivery also helps address health inequities, meeting the needs of people who are not suitable or able to access more complex treatments in specialist centres. New financing maintains full momentum to registration studies. RA Capital Management and Pfizer Ventures now join Morningside as shareholders. Further additional contribution too from the American Cancer Society’s impact fund, BrightEdge. Total funding: $60.7m. Great to have Laura Stoppel of RA Capital joining the Board, as well as Irena Melnikova from Pfizer Ventures. Press release: https://lnkd.in/d9QpfvFz Endpoints coverage: https://lnkd.in/dg4geESK. Many thanks Lei Lei Wu Business Weekly: https://lnkd.in/e4ZsaJkA Many thanks Tony Quested #multiplemyeloma Debbie Haynes Tomasz Knurowski Karen Clegg Kris Frese Thea Stanway

56

1 Kommentar

Read our article in the European Biopharmaceutical Review (EBR) to learn more about how Just - Evotec Biologics is bringing #continuousbiomanufacturing to Europe.

8

After a successful Women in Advanced Therapies Global, What's next for Phacilitate? - 10th September (Estoril, Portugal) Women in Advanced Therapies Congress (Europe) Advanced Therapies Investment Summit (Europe) - 10-11-12th September (Estoril, Portugal) Advanced Therapies Europe - 20-21-22-23rd January 2025 (Dallas, Tx) Advanced Therapies Week #Phacilitate #AdvancedTherapiesWeek #AdvancedTherapiesEurope #ATW25 #ATE24 #celltherapy #genetherapy #cellandgenetherapies #ATMPs #AdvancedTherapies

33

2 Kommentarer

Thrilled to share results of an external validation, by researchers at Stanford University, of Deep Bio Inc.'s DeepDx Prostate AI algorithm on prostatectomy specimens. Interestingly, this algorithm was trained on CNB specimens and performed amazing well - "demonstrating almost perfect concordance with expert GU pathologists". Authors' Conclusions: The DeepDx Prostate AI algorithm is an accurate tool for identifying and grading prostate cancer on digital histopathology images of whole-mount RP specimens, demonstrating almost perfect concordance with expert GU pathologists and impressive performance in various clinically relevant tasks.

23

This was quite a track record of performance for Cybin over the past year: - Positive phase 2 safety and efficacy readout for CYB003 as an adjunctive treatment for MDD - Around 75% of MDD patients in remission after just two doses - sustained for at least 4 months - Breakthrough Therapy Designation awarded to CYB003 by FDA - Successful recruitment of 30 sites for an upcoming phase 3 study of CYB003 in MDD this summer - Closing and integration of the Small Pharma team, along with programs and IP - Acceleration of CYB004 IM formulation aimed at delivering a 90 minute experience - Initiation of a phase 2 study of CYB004 in GAD with top line results expected around year end 2024

64

15 Kommentarer